TNFRSF8 and classic Hodgkin lymphoma: The selective and dense CD30 expression on lymphomatous cells makes it an attractive target for drug-conjugated antibody-directed treatment, as their expression was reported previously in refractory cHL and later confirmed in animal models on ALCL [122,123].